Indian ATMP (Advanced Therapy Medicinal Products) Manufacturing MEP — EU EMA 1394/2007 + USFDA 21 CFR 1271 + Schedule M

A 10,000 m² Indian multi-product ATMP facility (MSC + tissue-engineered + CAR-T) demands ₹1,545 Cr MEP capex with MCB vault + WCB suite + bioreactor + Grade A in B fill + tissue scaffold fab + QC lab + cryopreservation + LIMS + segregated HVAC. EU EMA 1394/2007 + USFDA 21 CFR 1271 + Schedule M + ICH Q5 + ISCT + FACT-JACIE + WHO TRS 1019 + India RCGM govern. ATMP regulatory pathway 96 months concept-to-commercial. Three failures: single-use vs multi-use system selection not analysed, MCB vault security inadequate (shared vault) blocking IND filing, tissue-engineered biomaterial regulatory pathway not aligned to USFDA 21 CFR 1271 + EU MDR + CDSCO.

Indian ATMP manufacturing framework

Indian ATMP (Advanced Therapy Medicinal Products) — Mesenchymal stem cell (MSC) therapy + tissue-engineered products + biologic implants + Engineered T-cell. India players — Stempeutics + Reliance Life Sciences + Cellsure + Stemfit + Eyestem. Standards stack — EU EMA ATMP Regulation 1394/2007 + USFDA 21 CFR 1271 + Schedule M 2023 + ICH Q5A + ISCT (International Society for Cell + Gene Therapy) + FACT-JACIE + WHO TRS 1019 + India RCGM Stem Cell Guidelines 2017 updates 2024.

Multi-product ATMP (MSC + Tissue-engineered + CAR-T) MEP scope — 10,000 m²

Three Indian ATMP manufacturing MEP failures

1. Single-use vs multi-use system selection not analysed — ATMP allows both — single-use cuts cross-contamination risk but adds plastic waste + cost. Multi-use needs full CIP + SIP validation per batch + 21 CFR 211. Indian sites default to multi-use without proper validation — face USFDA cGMP issues.
2. Master cell bank vault security inadequate — MCB is the irreplaceable foundation. Requires biometric access + redundant cryostorage + monitored alarm + insurance documentation. Indian R&D facilities sometimes have shared vault — face IND/NDA filing rejection.
3. Tissue-engineered scaffold biomaterial regulatory pathway not aligned — collagen + decellularised matrix + biomaterials must comply with USFDA 21 CFR 1271 + EU MDR + India CDSCO Medical Device classification. Indian R&D sometimes lacks clarity + faces commercial pathway delay.